Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Biotechnology

Healthcare
$305.19 +4.49%

+$12.13 today

Market cap
$8.53B
Beta
2.75
P/E (TTM)
-25.0
EPS (TTM)
-$11.31
52W Low $37.19High $366.52

Volume 0.43M

Average 0.45M

PRAX Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Praxis Precision Medicines, Inc.NASDAQ: PRAX

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin not reported for Q3 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMSep 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2024
-2340.3%
Year-over-year change
+2824.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How PRAX compares with its peers on the latest reported figures

PRAX Competitors Peer median
Operating Margin for PRAX and competitors
Company Period LTM level YoY 3-year change
NBIXNeurocrine Biosciences, Inc.LTM Sep 202623.8% +3.3 pp+4.9 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202610.2% -12.8 pp+53.0 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-13.5% -23.1 pp-12.0 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-24.3% +22.0 pp+332.8 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-611.0% ——
XENEXenon Pharmaceuticals Inc.FY2025-4974.3% —-3605.4 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-15058.2% ——
PRAXPraxis Precision Medicines, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding PRAX) -24.3%-4.8 pp+4.9 pp

Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue002.45M8.55M0
Cost of Revenue0154.44M86.77M152.41M140K
Gross Profit0(154.44M)(84.32M)(143.86M)(140K)
Gross Margin——-3445.8%-1682.0%—
Research & Development120.26M155.04M86.77M152.41M267.12M
Selling, General & Admin47.08M59.55M42.05M56.31M59.08M
Operating Expenses167.33M60.55M42.05M56.31M326.06M
Depreciation & Amortization182K419K432K358K140K
EBITDA(166.88M)(213.57M)(122.85M)(182.46M)(303.13M)
EBITDA Margin——-5020.2%-2133.3%—
Operating Income(167.33M)(214.99M)(126.37M)(200.17M)(326.2M)
Operating Margin——-5164.4%-2340.3%—
Interest Income00017.35M22.93M
Interest Expense00000
Other Income / Expenses271K957K3.1M17.35M22.93M
Income Before Tax(167.06M)(214.03M)(123.28M)(182.82M)(303.27M)
Pre-Tax Margin——-5037.9%-2137.5%—
Income Tax Expense00000
Net Income(167.06M)(214.03M)(123.28M)(182.82M)(303.27M)
Net Margin——-5037.9%-2137.5%—
EPS (Basic)(58.96)(69.33)(18.69)(10.21)(13.48)
EPS (Diluted)(58.96)(69.33)(18.69)(10.21)(13.48)
Weighted Avg Shares2.83M3.07M6.59M17.91M22.5M
Weighted Avg Shares (Diluted)2.83M3.07M6.59M17.91M22.5M

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Intrinsic Alpha fair value

Locked

Current Price

$305.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.